Squarepoint
TNXP icon

Squarepoint’s Tonix Pharmaceuticals TNXP Stock Holding History

Squarepoint’s Portfolio TNXP Stock Details TNXP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-31,633
Closed -$764K – 4898
2025
Q3 		$764K Buy
+31,633
New +$1.17M ﹤0.01% 2896
2025
Q1 		– Sell
-468
Closed -$15.4K – 5420
2024
Q4 		$15.4K Buy
+468
New +$9.7K ﹤0.01% 4947
2022
Q3 		– Sell
-2
Closed -$75K – 3443
2022
Q2 		$75K Buy
+2
New +$148K ﹤0.01% 2668
2022
Q1 		– Hold
0
– -$12K – 3530
2021
Q4 		– Hold
0
– – – 3099
2021
Q3 		– Hold
0
– – – 2835
2021
Q1 		– Sell
-1
Closed -$459K – 3622
2020
Q4 		$459K Buy
+1
New +$410K ﹤0.01% 1877
2020
Q3 		– Hold
0
– – – 1912

Other funds holding TNXP

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Davidson Kempner Capital Management
Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return

Squarepoint's TNXP Position: Q4 2025 in Review

Squarepoint sold out of Tonix Pharmaceuticals (TNXP) in Q4 2025, closing a stake of 31,633 shares — an estimated $764K sold.

Squarepoint first reported a position in TNXP in Q4 2020 and held it in 4 quarters. The position peaked at $764K in Q3 2025. 70 funds tracked by Wall St. Rank hold TNXP as of Q4 2025.

  • Squarepoint reported no remaining Tonix Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Squarepoint sold 31,633 Tonix Pharmaceuticals shares in Q4 2025, an estimated $764K.
  • Squarepoint first reported a position in Tonix Pharmaceuticals in Q4 2020 and held it in 4 quarters.
  • Squarepoint's Tonix Pharmaceuticals position peaked at $764K in Q3 2025.
  • 70 funds tracked by Wall St. Rank held Tonix Pharmaceuticals as of Q4 2025.

Based on Squarepoint's 13F filing for Q4 2025, filed 13 Feb 2026.